Elevation Oncology

📍 New York, United States🗓 Founded 2019👥 34 employees💰 Last funded Aug 2019
Biotechnology🌐 elevationoncology.com
Website LinkedIn
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient’s unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Elevation Oncology?
Elevation Oncology has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Elevation Oncology last raise funding?
The most recent investment in Elevation Oncology recorded on gritt.io was in August 2019.
When was Elevation Oncology founded?
Elevation Oncology was founded in 2019.
What industry is Elevation Oncology in?
Elevation Oncology operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Elevation Oncology based?
Elevation Oncology is headquartered in New York, United States.